@cdoyle
" The ongoing Phase III APPLAUSE-IgAN study is evaluating the efficacy and safety of twice-daily oral Fabhalta (200 mg) versus placebo in adult IgAN patients on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i."
"Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)." [no idea where you get 35% from- the placebo adjusted is reported as 38%, it's not 44-9 because of how the means are calculated statistically I believe, do you understand what placebo-adjusted is??]
https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan
Please learn to read, and stop embarrassing yourself!!!!
- Forums
- ASX - By Stock
- DXB
- Banter and general comments
Banter and general comments, page-40
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 26318 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 170072 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1318 | 0.380 |
3 | 72579 | 0.375 |
4 | 134161 | 0.370 |
1 | 30000 | 0.365 |
4 | 27499 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 140963 | 5 |
0.395 | 61740 | 2 |
0.400 | 115000 | 2 |
0.405 | 86528 | 4 |
0.410 | 56400 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |